Royalty Pharma EBITDA vs. Number Of Shares Shorted
| RPRX Stock | USD 25.54 0.14 0.55% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 1.9 B | Current Value 1.8 B | Quarterly Volatility 441.6 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.69 | 0.7619 |
|
| |||||
| Net Profit Margin | 0.54 | 0.482 |
|
| |||||
| Operating Profit Margin | 0.54 | 0.6337 |
|
| |||||
| Pretax Profit Margin | 0.75 | 0.722 |
|
| |||||
| Return On Assets | 0.079 | 0.0693 |
|
| |||||
| Return On Equity | 0.19 | 0.1739 |
|
|
For Royalty Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Royalty Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Royalty Pharma Plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Royalty Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Royalty Pharma Plc over time as well as its relative position and ranking within its peers.
Royalty |
Royalty Pharma's Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.587 | Dividend Share 0.83 | Earnings Share 2.54 | Revenue Per Share 5.055 | Quarterly Revenue Growth 0.053 |
The market value of Royalty Pharma Plc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty Pharma's value that differs from its market value or its book value, called intrinsic value, which is Royalty Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty Pharma's market value can be influenced by many factors that don't directly affect Royalty Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Royalty Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Royalty Pharma Plc Number Of Shares Shorted vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Royalty Pharma's current stock value. Our valuation model uses many indicators to compare Royalty Pharma value to that of its competitors to determine the firm's financial worth. Royalty Pharma Plc is currently regarded as top stock in ebitda category among its peers. It is rated second in number of shares shorted category among its peers making about 0.01 of Number Of Shares Shorted per EBITDA. The ratio of EBITDA to Number Of Shares Shorted for Royalty Pharma Plc is roughly 120.62 . At this time, Royalty Pharma's EBITDA is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Royalty Pharma's earnings, one of the primary drivers of an investment's value.Royalty Number Of Shares Shorted vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Royalty Pharma |
| = | 1.89 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Royalty Pharma |
| = | 15.65 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Royalty Number Of Shares Shorted Comparison
Royalty Pharma is currently under evaluation in number of shares shorted category among its peers.
Royalty Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Royalty Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Royalty Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Royalty Pharma's change in net profit over the period of time. It can combine multiple indicators of Royalty Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 72.5 K | 68.8 K | |
| Operating Income | 1.5 B | 1.1 B | |
| Net Income From Continuing Ops | 1.7 B | 1.1 B | |
| Income Before Tax | 1.7 B | 1.1 B | |
| Total Other Income Expense Net | 207.9 M | 218.3 M | |
| Net Income Applicable To Common Shares | 49.3 M | 46.8 M | |
| Net Income | 1.1 B | 1.1 B | |
| Income Tax Expense | 565.3 M | 438.6 M | |
| Net Interest Income | -114.9 M | -120.6 M | |
| Interest Income | 72.3 M | 45 M | |
| Non Operating Income Net Other | 99.9 M | 93.7 M | |
| Change To Netincome | 57.7 M | 60.6 M | |
| Net Income Per Share | 2.54 | 2.53 | |
| Income Quality | 2.63 | 2.01 | |
| Net Income Per E B T | 0.67 | 0.70 |
Royalty Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Royalty Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Royalty Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Royalty Pharma's important profitability drivers and their relationship over time.
Use Royalty Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Royalty Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will appreciate offsetting losses from the drop in the long position's value.Royalty Pharma Pair Trading
Royalty Pharma Plc Pair Trading Analysis
The ability to find closely correlated positions to Royalty Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Royalty Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Royalty Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Royalty Pharma Plc to buy it.
The correlation of Royalty Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Royalty Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Royalty Pharma Plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Royalty Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Royalty Pharma position
In addition to having Royalty Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.